Progress update: Post-market Review (PMR) of medicines for smoking cessation
Page last updated: 12 November 2021
In June 2021, the Drug Utilisation Sub-Committee (DUSC) and the Economics Sub-Committee (ESC) of the Pharmaceutical Benefits Advisory Committee (PBAC) considered the Report for the Post-market Review (PMR) of medicines for smoking cessation. The ESC requested that cost-effectiveness evaluations of combination therapies be conducted, as proposed in the Review options. The department has contracted an external evaluation group to conduct a cost-effectiveness review (CER) of combinations of smoking cessation medicines. The CER will be considered by the ESC in early 2022.
The PMR and additional CER will then be provided to the PBAC for consideration in 2022.
Further information on the PMR of medicines for smoking cessation is available on the PBS website.